A bill to amend the Public Health Service Act with respect to the drug discount program, and for other purposes.
Summary
S5244, a bill to amend the Public Health Service Act regarding the drug discount program (340B), was introduced on August 5, 2026, and referred to the Senate HELP Committee. At this early stage, no specific market impact can be determined; the bill lacks detailed text and has not moved beyond committee referral.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S5244 is in the earliest legislative stage with no actionable details on 340B program changes.
- 2.Bipartisan cosponsorship suggests potential for progress, but no market-moving information is available yet.
- 3.Investors should wait for committee markup or released bill text before assessing impact on pharmaceutical or hospital stocks.
Market Implications
There are no current market implications from S5244. The bill is at the referral stage, and without text or committee action, it does not affect any company's revenue or competitive position. Investors in healthcare sectors (pharmaceuticals, hospitals, PBMs) should monitor the HELP Committee for future developments.
Full Analysis
Senator Moran (R-KS) introduced S5244 on August 5, 2026, with bipartisan cosponsorship from Senators Baldwin (D-WI), Capito (R-WV), Kaine (D-VA), Boozman (R-AR), and Hickenlooper (D-CO). The bill aims to amend the Public Health Service Act with respect to the drug discount program, commonly known as 340B. The 340B program requires drug manufacturers to provide outpatient drugs at discounted prices to covered entities (hospitals serving low-income populations). The bill's specific provisions are not publicly available at this stage. It has been read twice and referred to the Committee on Health, Education, Labor, and Pensions (HELP). No further legislative actions have occurred. As an early-stage authorization bill with no explicit funding amount, it does not directly allocate money. The legislative path includes committee hearings, markup, floor consideration, and potential House passage. Given the early stage and lack of detail, no concrete market impact can be assessed. Investors should monitor committee activity for amendments or a full bill text that would clarify whether the program is expanded, restricted, or otherwise modified.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To establish an eligibility exception for the drug discount program due to cuts to the Medicaid program.
To strengthen the 340B drug discount program.
Community Health Center Drug Pricing Protection Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →